BACKGROUND: Drug-resistant Plasmodium falciparum malaria necessitates development of novel drugs for treatment.The present study assessed the efficacy and safety of 3 dose levels of arterolane (RBx 11160), a synthetic trioxolane, for treatment of acute uncomplicated falciparum malaria. METHODS: In this randomized, double-blind, multicenter, parallel-group, dose-finding, phase II trial, 230 patients from 4 centers in Thailand, India, and Tanzania (mainland and Zanzibar) received either 50 mg (n=78), 100mg (n=76), or 200 mg (n=76) of arterolane once daily for 7 days. Patients (aged 13-65 years) with asexual parasite density of 1000-100,000 parasites/microL were included and were followed up for 28 days. The median time to 90% parasite clearance (PC90) was evaluated. RESULTS: The median PC90 was longer in the group receiving the 50-mg dose (19.4 h), compared with the groups receiving the 100-mg dose (12.8 h) and 200-mg dose (12.6 h) (P < .01). The polymerase chain reaction-corrected adequate clinical and parasitological responses on day 28 were 63%, 71%, and 72% for the groups receiving the 50-mg, 100-mg, and 200-mg doses, respectively, by intention-to-treat analysis (odds ratio, 1.55; 95%confidence interval, 0.78-3.06, for comparison of the 200-mg and 50-mg dose groups). Treatment was generally well tolerated. No patient died or experienced any serious adverse event. Mild complaints were reported in <10%of the patients and were similar in the 3 groups. Biochemistry and hematological analyses did not show any signof drug toxicity in any patient. CONCLUSION: Arterolane at daily doses of 100 and 200 mg is a rapidly acting, effective, and safe synthetic antimalarial drug, which may potentially represent an alternative to artemisinin derivatives in antimalarial combination therapy. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT00362050.
RCT Entities:
BACKGROUND: Drug-resistant Plasmodium falciparum malaria necessitates development of novel drugs for treatment.The present study assessed the efficacy and safety of 3 dose levels of arterolane (RBx 11160), a synthetic trioxolane, for treatment of acute uncomplicated falciparum malaria. METHODS: In this randomized, double-blind, multicenter, parallel-group, dose-finding, phase II trial, 230 patients from 4 centers in Thailand, India, and Tanzania (mainland and Zanzibar) received either 50 mg (n=78), 100mg (n=76), or 200 mg (n=76) of arterolane once daily for 7 days. Patients (aged 13-65 years) with asexual parasite density of 1000-100,000 parasites/microL were included and were followed up for 28 days. The median time to 90% parasite clearance (PC90) was evaluated. RESULTS: The median PC90 was longer in the group receiving the 50-mg dose (19.4 h), compared with the groups receiving the 100-mg dose (12.8 h) and 200-mg dose (12.6 h) (P < .01). The polymerase chain reaction-corrected adequate clinical and parasitological responses on day 28 were 63%, 71%, and 72% for the groups receiving the 50-mg, 100-mg, and 200-mg doses, respectively, by intention-to-treat analysis (odds ratio, 1.55; 95%confidence interval, 0.78-3.06, for comparison of the 200-mg and 50-mg dose groups). Treatment was generally well tolerated. No patient died or experienced any serious adverse event. Mild complaints were reported in <10%of the patients and were similar in the 3 groups. Biochemistry and hematological analyses did not show any signof drug toxicity in any patient. CONCLUSION:Arterolane at daily doses of 100 and 200 mg is a rapidly acting, effective, and safe synthetic antimalarial drug, which may potentially represent an alternative to artemisinin derivatives in antimalarial combination therapy. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT00362050.
Authors: Charlotte A Lanteri; Suwanna Chaorattanakawee; Chanthap Lon; David L Saunders; Wiriya Rutvisuttinunt; Kritsanai Yingyuen; Ian Bathurst; Xavier C Ding; Stuart D Tyner Journal: Antimicrob Agents Chemother Date: 2014-07-21 Impact factor: 5.191
Authors: Anupkumar R Anvikar; Usha Arora; G S Sonal; Neelima Mishra; Bharatendu Shahi; Deepali Savargaonkar; Navin Kumar; Naman K Shah; Neena Valecha Journal: Indian J Med Res Date: 2014-02 Impact factor: 2.375
Authors: Susan A Charman; Darren J Creek; Carlo Giannangelo; Lukas Stingelin; Tuo Yang; Leann Tilley Journal: Antimicrob Agents Chemother Date: 2018-02-23 Impact factor: 5.191
Authors: Susan A Charman; Sarah Arbe-Barnes; Ian C Bathurst; Reto Brun; Michael Campbell; William N Charman; Francis C K Chiu; Jacques Chollet; J Carl Craft; Darren J Creek; Yuxiang Dong; Hugues Matile; Melanie Maurer; Julia Morizzi; Tien Nguyen; Petros Papastogiannidis; Christian Scheurer; David M Shackleford; Kamaraj Sriraghavan; Lukas Stingelin; Yuanqing Tang; Heinrich Urwyler; Xiaofang Wang; Karen L White; Sergio Wittlin; Lin Zhou; Jonathan L Vennerstrom Journal: Proc Natl Acad Sci U S A Date: 2011-02-07 Impact factor: 11.205
Authors: Edgar Deu; Ingrid T Chen; Erica M W Lauterwasser; Juan Valderramos; Hao Li; Laura E Edgington; Adam R Renslo; Matthew Bogyo Journal: Proc Natl Acad Sci U S A Date: 2013-10-21 Impact factor: 11.205
Authors: Melinda P Anthony; Jeremy N Burrows; Stephan Duparc; Joerg J Moehrle; Timothy N C Wells Journal: Malar J Date: 2012-09-07 Impact factor: 2.979